News AZ highlights data from next-gen oncology drugs at ASCO Tesara and Takeda among other companies to publish data.
News Doubts over AbbVie PARP inhibitor after double trial failure Veliparib fails in two phase 3 trials.
News Tesaro's niraparib approved in ovarian cancer Company nabs maintenance therapy use, but problems on breast cancer trial.
News AZ's Lynparza impresses with new ovarian cancer data UK firm lays down the gauntlet in the PARP inhibitor battle.
News Praxis soars on rare childhood epilepsy trial data Praxis looks like it could be filing for approval of two products next year, after its childhood epilepsy drug delivered a win in a pivotal trial.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
